Stockscreener 앱 받기
72.15
1.53%
1.09
시간 외 거래:
72.44
0.29
+0.40%
전일 마감가:
$71.06
열려 있는:
$71.17
하루 거래량:
545.68K
Relative Volume:
0.59
시가총액:
$5.77B
수익:
$58.89M
순이익/손실:
$-240.88M
주가수익비율:
-23.27
EPS:
-3.1
순현금흐름:
$-239.96M
1주 성능:
+5.88%
1개월 성능:
-11.28%
6개월 성능:
+57.57%
1년 성능:
+75.04%
1일 변동 폭
$71.14
$73.15
1주일 범위
$67.76
$73.15
52주 변동 폭
$19.45
$103.00
Kymera Therapeutics Inc Stock (KYMR) Company Profile
명칭
Kymera Therapeutics Inc
전화
857-285-5314
주소
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
KYMR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
72.15 | 5.68B | 58.89M | -240.88M | -239.96M | -3.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-06 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-11-03 | 재개 | Guggenheim | Buy |
| 2025-10-24 | 재확인 | B. Riley Securities | Buy |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-16 | 개시 | RBC Capital Mkts | Outperform |
| 2025-07-30 | 재개 | B. Riley Securities | Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-06-03 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-05-20 | 재개 | Stifel | Buy |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Market Perform |
| 2024-12-02 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-26 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | 개시 | Oppenheimer | Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-01-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | 개시 | Truist | Buy |
| 2023-05-05 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | 개시 | Raymond James | Mkt Perform |
| 2022-08-15 | 개시 | Jefferies | Buy |
| 2022-08-03 | 개시 | Goldman | Buy |
| 2022-07-20 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-28 | 개시 | Credit Suisse | Outperform |
| 2022-03-10 | 개시 | JP Morgan | Neutral |
| 2022-02-10 | 개시 | Wells Fargo | Overweight |
| 2021-09-30 | 개시 | B. Riley Securities | Neutral |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-09-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-14 | 개시 | Berenberg | Buy |
| 2020-12-04 | 개시 | H.C. Wainwright | Buy |
| 2020-09-15 | 개시 | BofA Securities | Neutral |
| 2020-09-15 | 개시 | Cowen | Outperform |
| 2020-09-15 | 개시 | Guggenheim | Buy |
| 2020-09-15 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Kymera Therapeutics Inc 주식(KYMR)의 최신 뉴스
Responsive Playbooks and the KYMR Inflection - Stock Traders Daily
Aug Volume: What is the long term forecast for Kymera Therapeutics Inc stockWall Street Watch & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Assessing Kymera Therapeutics (KYMR) Valuation After Milestone Updates For KT-621 And Partnered IRAK4 Programs - Sahm
Is BRID stock overvalued or fairly pricedJuly 2025 Sentiment & Community Trade Idea Sharing Platform - baoquankhu1.vn
Kymera Therapeutics director Esposito sells $373k in shares By Investing.com - Investing.com Nigeria
Kymera Therapeutics director Esposito sells $373k in shares - Investing.com
This drugmaker's stock is soaring over 40% Monday - MSN
Signal Recap: Does Loop Industries Inc outperform in volatile marketsMarket Activity Report & Safe Swing Trade Setups - baoquankhu1.vn
Exit Recap: Can Kymera Therapeutics Inc benefit from deglobalizationJuly 2025 Chart Watch & Real-Time Stock Entry Alerts - baoquankhu1.vn
Portfolio Update: What is Kymera Therapeutics Incs 5 year growth outlookWeekly Earnings Recap & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Kymera Therapeutics, Inc. (KYMR) up 28% in 3M, analysts see further upside - MSN
Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (25 Ratings) - Benzinga
BTIG Reiterates Buy Rating for Kymera Therapeutics (KYMR) with $ - GuruFocus
Kymera Therapeutics, Inc. (KYMR) Up 28% in 3M, Analysts See Further Upside - Finviz
Muted and missing M&As: JPM deals absent in 2026 - BioWorld MedTech
BTIG Research Reaffirms Buy Rating for Kymera Therapeutics (NASDAQ:KYMR) - MarketBeat
Kymera Therapeutics prices $602M public offering at $86.00 a share - MSN
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Portfolio of Oral Immunology Programs - marketscreener.com
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs - Investing News Network
Kymera Therapeutics Sets 2026 Clinical Strategy and Milestones - TipRanks
Kymera Therapeutics (KYMR): Investor Outlook On Biotech's 59.75% Upside Potential - DirectorsTalk Interviews
Kymera Therapeutics Outlines 2026 Milestones, Advances Clinical Trials for Immunology Candidates - Quiver Quantitative
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs - GlobeNewswire Inc.
Eczema and asthma pill trials shape Kymera’s $1.6B 2026 strategy goals - Stock Titan
Understanding the Setup: (KYMR) and Scalable Risk - Stock Traders Daily
Kymera Therapeutics (KYMR) Upgraded to Buy: Here's Why - Yahoo Finance
Morgan Stanley Maintains Hold Rating on Kymera Therapeutics (KYMR), Keeps PT - MSN
Will Kymera Therapeutics Inc. stock maintain growth storyFootwear buying guidance for outdoor walking and light jogging focuses on support for wide feet, making it recommended when comfort and support matter. - ulpravda.ru
Why Kymera Therapeutics Inc. stock could see breakout soonMarket Trend Summary & Technical Buy Zone Confirmations - Улправда
Why Kymera Therapeutics Inc. stock is trending among retail traders2025 Price Momentum & AI Powered Buy/Sell Recommendations - Улправда
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Is Kymera Therapeutics (KYMR) Balancing Pipeline Ambition and Execution Risk After New KT-621 Milestone? - Yahoo Finance
Kymera Advances KT-621 Into Mid-Stage Asthma Trial, Setting Up a New Catalyst for KYMR Investors - TipRanks
Kymera jumps on early-stage data for eczema candidate KT-621 - MSN
Kymera Therapeutics, Inc. (KYMR) Stock Analysis: A Biotech Leader with a 59.70% Potential Upside - DirectorsTalk Interviews
Kymera Therapeutics (KYMR) Downgraded by Wolfe Research | KYMR S - GuruFocus
Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 - Investing News Network
Kymera Therapeutics CEO to unveil 2026 milestones at JPMorgan event - Traders Union
Wolfe Research downgrades Kymera Therapeutics stock rating on lack of catalysts - Investing.com Canada
KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026? - sharewise.com
Kymera Therapeutics stock extends slide as KYMR closes down 6.5% — what investors watch next - TechStock²
Kymera Therapeutics (KYMR) stock drops 6.6% to start 2026 as insider sale filing stays in focus - ts2.tech
KYMR Stock Falls -14% With A 7-day Losing Spree On Significant Insider Selling - Trefis
Kymera Therapeutics stock slides nearly 7% after CEO share-sale filing — what KYMR investors watch next - ts2.tech
Kymera Therapeutics (NASDAQ:KYMR) Trading Down 4.3%What's Next? - MarketBeat
Kymera Therapeutics (KYMR) Sees 4% Drop in Stock Price - GuruFocus
Kymera Therapeutics Inc (KYMR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.09%
0.48%
자본화:
|
볼륨(24시간):